54 results
PRE 14A
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
10 Apr 24
Preliminary proxy
5:00pm
be offset by any net operating losses for such years, and gains recognized on the sale or other disposition of our shares cannot be treated as capital
8-K
EX-99.2
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
2 Apr 24
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
7:32am
Initial Duration of Therapy ~12 Months1
Growth in Total Patients on ARCALYST Therapy Acceleration in new-to-brand and restart patients offset higher
8-K
EX-99.2
dh5axjabb 346x
4 Jan 24
Kiniksa Pharmaceuticals Provides Corporate Update
7:37am
DEFA14A
0gud3a46uwaltm6
28 Apr 21
Additional proxy soliciting materials
4:08pm